Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL -Rearranged Acute Lymphoblastic Leukemia

8 Jan 2015

Abstract excerpt

PURPOSE: Although the overall cure rate for pediatric acute lymphoblastic leukemia (ALL) approaches 90%, infants with ALL harboring translocations in the mixed-lineage leukemia (MLL) oncogene (infant MLL-ALL) experience shorter remission duration and lower survival rates (∼50%). Mutations in the p53 tumor-suppressor gene are uncommon in infant MLL-ALL, and drugs that release p53 from inhibitory mechanisms may be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Carcinogens and Genotoxicity Assessment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25573381
DOI: 10.1158/1078-0432.ccr-14-2300

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL -Rearranged Acute Lymphoblastic LeukemiaPMID 25573381Read ↗

Updates in the biology and therapy for infant acute lymphoblastic leukemiaSemantic proximity Read ↗

Towards targeted therapy for infant acute lymphoblastic leukaemia.Semantic proximity Read ↗

Gene expression profiling–based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infantsSemantic proximity Read ↗

Therapies on the horizon for childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.Semantic proximity Read ↗

Treatment of infant leukemias: challenge and promiseSemantic proximity Read ↗

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemiaSemantic proximity Read ↗

The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.Semantic proximity Read ↗

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia.Semantic proximity Read ↗

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

In Vivo Response to Methotrexate Forecasts Outcome of Acute Lymphoblastic Leukemia and Has a Distinct Gene Expression ProfileSemantic proximity Read ↗

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.